GRB10

(redirected from IRBP)
Also found in: Acronyms.

GRB10

A gene on chromosome 7p12.2 that encodes an adapter protein which binds to, and suppresses signals from, activated receptors tyrosine kinases—e.g., insulin and insulin-like growth factor receptors (INSR and IGF1R, respectively)—by either interfering with the signalling pathway or increasing receptor degradation. It also downregulates Wnt signalling by interfering with the binding of AXIN1 to LRP6, and it may inhibit NEDD4-mediated degradation of KDR/VEGFR-2. GRB10 upregulates the KDR/VEGFR-2 signalling pathway.
References in periodicals archive ?
IRBP is in discussions with leading pharmacies to be the pharmacy manager for Remune HIV/AIDS vaccine distribution whether for expanded IND or compassionate use treatment prior to FDA approval or FDA BLA commercialization.
IRBP expects the FDA to be cooperative & provide a constructive path forward to move the Remune FDA BLA towards approval.
IRBP continues to be focused on Remune commercialization and FDA approval of the FDA BLA & will be the main focus of the company.
I am energized by our FDA BLA filing and FDA acceptance of our application, the road to a true pure whole killed HIV vaccine for the government comes through IRBP & Remune.
The IRBP 141 allele occurred only in the Cote-Nord population in Quebec (Table 1).
IRBP Executed Two New CDA's with mid size Pharmaceutical companies
IRBP Selected Seppic to provide IFA for Remune Commercialization & clinical pipeline
IRBP Plans new Psoriasis Vaccine Phase IIb Study as Development on Track for Zorcell & DermaVax formulations as Dr.
IRBP to Develop Sales Force for Remune Commercialization
IRBP Filed its Breakthrough IND Application with the FDA for the Remune Pediatric Phase II Protocol with the FDA & Applying for FDA Orphan Pediatric Grant Funding
IRBP is Planning a NeuroVax MS Phase I Pediatric Study submitting Protocol to the FDA for Approval of the Study & Applying for FDA Orphan Pediatric Grant Funding
IRBP Filed BLA with the FDA for Commercial Marketing Approval of Remune HIV/AIDS Vaccine for Therapeutic HIV/AIDS Treatment on December 19th 2014 & used its SBA FDA fee waiver